Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at :

NCT ID NCT06365853
Title A Study of Ocular Toxicity Evaluation and Mitigation During Treatment With Mirvetuximab Soravtansine in Participants With Recurrent Ovarian Cancer With High Folate Receptor-Alpha Expression
Recruitment Not yet recruiting
Gender female
Phase Phase II
Variant Requirements No
Sponsors ImmunoGen, Inc.
Age Groups: senior | adult
Covered Countries USA | ITA | FRA | ESP | CAN | BEL | AUS

No variant requirements are available.